Friday, May 3, 2024
5/3/2024
Project Summary Tumor immunotherapies represent the most exciting advance for cancer patients in recent decades. However, only a minor proportion of treated patients experience long-lasting benefits from current tumor immunotherapies. A subset of tumor-specific T lymphocytes carrying features of memory or progenitor T cells has been named “stem-like” T cells. These stem-like T cells are essential to sustain anti-tumor T cell immunity and are the major responder to several current tumor immunotherapies. Thus, a better understanding of these stem-like T cells will greatly facilitate the improvement of current therapies or the development of future tumor immunotherapies. Tissue-resident memory T cells (TRM) are a subset of non-circulating memory T cells initially discovered after acute infections. Recently, we have discovered that stem-like T cells differentiate into tissue-resident T cells inside tumor-draining lymph nodes, which is negatively associated with the response to tumor vaccine. In other words, a large number of stem-like T cells lose migratory capacity and are trapped inside tumor-draining lymph nodes. However, several open questions remain to be addressed regarding this newly discovered feature of stem- like T cells. For example, what is the lineage relationship between this TRM-stem T cell subsets and other T cells inside tumor-draining lymph nodes? Is there a connection between TRM-stem in TDLN and stem-like T cells inside the tumor microenvironment? Whether can we manipulate TRM program of stem-like T cells to boost tumor vaccine? In this application, we will use multiple well-established tumor models to track tumor-specific CD8+ T cell response in the presence and absence of tumor vaccination. We will answer this series of questions focusing on this unique T cell subset, i.e., TRM-stem. Further, our proposal will primarily focus on tumor-draining lymph nodes, which serve as a reservoir for tumor-specific stem-like T cells. Our proposed studies will greatly advance our understanding of stem-like T-cell biology. Importantly, we will establish a new targeting organ (tumor-draining lymph nodes) and a novel target (the lymphoid residency program of stem-like T cells) to boost the efficacy of tumor vaccine.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
